Citigroup Inc Morphic Holding, Inc. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Citigroup Inc holds 190,345 shares of MORF stock, worth $6.49 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

190,345

Previous 87,333 117.95%

Holding current value

$6.49 Million

Previous $2.52 Million 165.66%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$26.64 - $40.31 $2.74 Million - $4.15 Million	103,012 Added 117.95%	190,345 $6.7 Million
Q4 2023 Feb 09, 2024	BUY	$19.95 - $31.0 $542,979 - $843,727	27,217 Added 45.27%	87,333 $2.52 Million
Q3 2023 Nov 09, 2023	BUY	$21.33 - $59.42 $285,523 - $795,396	13,386 Added 28.65%	60,116 $1.38 Million
Q2 2023 Aug 10, 2023	SELL	$34.33 - $62.11 $32,201 - $58,259	-938 Reduced 1.97%	46,730 $2.68 Million
Q1 2023 May 11, 2023	SELL	$26.01 - $48.69 $24,345 - $45,573	-936 Reduced 1.93%	47,668 $1.79 Million

Q4 2022 Feb 09, 2023	SELL	$24.14 - $30.37 $909,667 - $1.14 Million	-37,683 Reduced 43.67%	48,604 $1.3 Million
Q3 2022 Nov 10, 2022	BUY	$22.23 - $33.37 $71,691 - $107,618	3,225 Added 3.88%	86,287 $2.44 Million
Q2 2022 Aug 10, 2022	BUY	$19.74 - $43.01 $1.4 Million - $3.04 Million	70,732 Added 573.66%	83,062 $1.8 Million
Q1 2022 May 12, 2022	SELL	$36.25 - $52.02 $1.26 Million - $1.8 Million	-34,687 Reduced 73.78%	12,330 $495,000
Q4 2021 Feb 10, 2022	BUY	$43.27 - $65.72 $1.14 Million - $1.73 Million	26,254 Added 126.45%	47,017 $2.23 Million
Q3 2021 Nov 10, 2021	BUY	$53.61 - $67.5 $1.11 Million - $1.4 Million	20,763 New	20,763 $1.18 Million

Others Institutions Holding MORF

# of Institutions

142

Shares Held

37.9M

Call Options Held

13.5K

Put Options Held

190K

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $1.31B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account